The scene at the FDA hearing was familiar. All the advisory committees have seen it play out again and again. Yesterday, it was the Pulmonary-Allergy Drug committee: The pharma doc with the convincing statement. The weeping patients. The drug likely to cost a couple thousand a month offering a slim benefit over an existing drugs. But it works, and it’s safe.
From the Globe:
“I think this is a much-needed advance for patients with cystic fibrosis,” said committee member Dr. Michelle S. Harkins, associate professor of medicine at the University of New Mexico Albuquerque, one of the majority voting to recommend approval.
The lone dissenter in the 12-1 vote recommending approval of the drug, Dr. Yanling Yu, the president and cofounder of Washington Advocates for Patient Safety in Seattle, said she was not convinced the data generated by the Vertex testing supported the approval of Orkambi.
“I really understand the patients critically need a new drug, but sometimes a new drug does not provide [the needed effectiveness],” she said.
From The New York Times story:
An issue for the advisory committee was that Orkambi had what the F.D.A. said was only modest effectiveness, improving lung function by only about 3 percentage points relative to placebo.
Some family members or advocates, some of them crying, pleaded with the committee to endorse the drug.
Some patients who took the drug in clinical trials said it had made a huge difference in their lives, reducing their coughing, allowing them to exercise better, helping them gain weight or reducing how often they ended up in the hospital…
Michael Yee of RBC Capital Markets, for instance, expects the price will be $225,000 to $250,000 a year.
The vote is advisory. The FDA staff will make the final call.